Concepedia

Vickie Bowcut

VB

6

Publications

2.6K

Citations

6

H-Index

2019

Active since

Affiliations

Mirati Therapeutics (United States)(Current)

Neurocrine Biosciences (United States)

Pfizer (United States)

Dana-Farber Cancer Institute

Vickie Bowcut is an author at Mirati Therapeutics (United States) specializing in medicine, radiation oncology, and lung cancer.

ORCID

Top concepts

Publications per year

2019–2024

6

Publications

6

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.2K citations · Full text

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor

Xiaolun Wang, Shelley Allen, James F. Blake et al. · Journal of Medicinal Chemistry · 2021 · 644 citations · Full text

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin, Vickie Bowcut, Andrew Calinisan et al. · Nature Medicine · 2022 · 465 citations

, , +7

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer

Lars D. Engstrom, Ruth Aranda, Laura Waters et al. · Cancer Discovery · 2023 · 163 citations · Full text

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction

John M. Ketcham, Jacob R. Haling, Shilpi Khare et al. · Journal of Medicinal Chemistry · 2022 · 87 citations · Full text

Rows per page

1–5 of 6